Bard Implanted Port Catheter

The Bard Implanted Port Catheter litigation, centralized before Judge David G. Campbell in the District of Arizona in August 2023, consolidates claims that implanted chemotherapy port catheters manufactured by Bard are prone to fracture, migrate, or otherwise fail inside the body, causing infection, vessel damage, and other internal injury in cancer patients relying on the devices for treatment access. With 3,734 actions pending, this is a large and increasingly mature docket: a bellwether process has already produced a real jury result — a $40 million verdict — and a third bellwether trial is scheduled for October 2026, giving funders and capital desks genuine outcome data to price against, which is a materially different position than a docket still awaiting its first verdict.

That bellwether track record matters directly for underwriting. A confirmed eight-figure verdict establishes that this defect theory can succeed before a jury, and the upcoming third trial will add another data point on how consistently that result holds across different plaintiffs and fact patterns. Funders should still expect case-by-case variation — device model, duration of implantation, and the nature and severity of the resulting injury or infection all affect individual claim value — but the existence of bellwether verdicts meaningfully narrows the uncertainty band compared with a docket that has not yet been tested in front of a jury.

Because claimants in this docket are cancer patients by definition, medical-lien exposure is often substantial and layered — oncology treatment, infection management, and any additional surgery required to remove or replace a failed port all generate lien claims that need to be sized carefully. For a firm holding a meaningful portfolio of Bard port catheter claims, the docket's bellwether history supports more confident portfolio-level underwriting than would be available earlier in the litigation's life. Criterica Capital's mass tort finance product, including portfolio-level structures, applies to claims in this docket, and a structural brief tracking the bellwether calendar is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.